Cancer Diagnostic
Dec 01, 2022
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery
AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States. The UriFind® bladder cancer assay clinical trial in the U...
Read More...
Jul 21, 2022
FDA Approval to Centinel’s Total Disc Replacement Devices; FDA clears DyAnsys’ Neurostimulator; Orthox to Commence FFLEX Study; Cordis Started Enrolment for RADIANCY Clinical Study; Orthofix & LimaCorporate Announce Partnership; Medtronic to Partner With AWS
Orthox Obtains MHRA Approval to Commence FFLEX Study On July 14, 2022, Orthodox Ltd, a clinical-stage company created medical implants to treat orthopedic problems including damaged knee articular cartilage. It was founded in 2008 by life scientist, Dr. Nick Skaer, and knee surgeon, Professor Oliver Kessle...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
